Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40FCP | ISIN: US81726A2096 | Ticker-Symbol:
NASDAQ
27.06.25 | 21:58
2,140 US-Dollar
+1,42 % +0,030
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SENTI BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
SENTI BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur SENTI BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.06.FDA grants orphan drug designation to Senti Bio's AML treatment4
18.06.Senti Biosciences, Inc. - 8-K, Current Report11
18.06.Senti Biosciences, Inc.: Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia121Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year1 with 60% of patients experiencing...
► Artikel lesen
09.06.Senti Biosciences, Inc.: Senti Biosciences Announces New Employment Inducement Grants73SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene...
► Artikel lesen
06.06.Senti Biosciences, Inc.: Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC2
SENTI BIOSCIENCES Aktie jetzt für 0€ handeln
06.06.Laidlaw startet Berichterstattung über Senti Biosciences-Aktie mit Kaufempfehlung4
06.06.Laidlaw initiates coverage on Senti Biosciences stock with buy rating1
22.05.Senti Biosciences, Inc.: Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar2
22.05.Senti Biosciences, Inc.: Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-2022
08.05.Senti Biosciences advances AML treatment with SENTI-202 trial1
08.05.Senti Biosciences macht Fortschritte bei AML-Behandlung mit SENTI-202-Studie1
08.05.Senti Biosciences, Inc.: Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-2021
06.05.Senti Biosciences, Inc. - 10-Q, Quarterly Report7
06.05.Senti Biosciences, Inc. - 8-K, Current Report1
06.05.Senti Biosciences, Inc.: Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development82Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated, preliminary RP2D identified; 4 of 7 patients achieved composite...
► Artikel lesen
01.05.Senti Biosciences, Inc.: Senti Bio Releases Virtual Investor "What This Means" Segment1
28.04.Senti Biosciences Stock Drops 23% Despite Positive Phase 1 Trial Update2
28.04.Senti Biosciences meldet vielversprechende Ergebnisse der SENTI-202-Studie2
28.04.Senti Biosciences, Inc. - 8-K, Current Report-
28.04.Senti Biosciences, Inc.: Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory ...1
Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1